EGFR and non-small cell lung carcinoma: The AURA3 trial was the first study to compare the central nervous system (CNS) efficacy of osimertinib with chemotherapy in T790M-positive advanced NSCLC patients with measurable CNS lesions who progressed on previous EGFR-TKI treatment, with a CNS ORR of 70% versus 31% and a median CNS PFS of 11.7 months versus 5.6 months in osimertinib and chemotherapy cohorts, respectively [227].